Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6935)
All Articles published online
|
Publishing Process of This Article
|
Jun 16, 2014 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ko SY, Naora H. Therapeutic strategies for targeting the ovarian tumor stroma. World J Clin Cases 2014; 2(6): 194-200 [PMID: 24945005 DOI: 10.12998/wjcc.v2.i6.194] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v2/i6/194.htm |
| Number | Citing Articles |
| 1 |
Wei-Min Chung, Yen-Ping Ho, Wei-Chun Chang, Yuan-Chang Dai, Lumin Chen, Yao-Ching Hung, Wen-Lung Ma. Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis. Cancers 2019; 11(4): 463 doi: 10.3390/cancers11040463
|
| 2 |
Wei-Min Chung, Lumin Chen, Wei-Chun Chang, Sheng-Yuan Su, Yao-Ching Hung, Wen-Lung Ma. Androgen/Androgen Receptor Signaling in Ovarian Cancer: Molecular Regulation and Therapeutic Potentials. International Journal of Molecular Sciences 2021; 22(14): 7748 doi: 10.3390/ijms22147748
|
| 3 |
Samuel S. Linton, Samantha G. Sherwood, Kelly C. Drews, Mark Kester. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. WIREs Nanomedicine and Nanobiotechnology 2016; 8(2): 208 doi: 10.1002/wnan.1358
|
| 4 |
Whitney Graybill, Anil K. Sood, Bradley J. Monk, Robert L. Coleman. State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer. Gynecologic Oncology 2015; 138(2): 223 doi: 10.1016/j.ygyno.2015.07.008
|
| 5 |
Charlotte Carlier, Sara Strese, Kristina Viktorsson, Ebba Velander, Peter Nygren, Maria Uustalu, Therese Juntti, Rolf Lewensohn, Rolf Larsson, Jack Spira, Elly De Vlieghere, Wim P. Ceelen, Joachim Gullbo. Preclinical activity of melflufen (J1) in ovarian cancer. Oncotarget 2016; 7(37): 59322 doi: 10.18632/oncotarget.11163
|
| 6 |
ChunXiao Yan, Yunshan Zhu, Xiao Zhang, Xuejun Chen, Wei Zheng, Jianhua Yang. Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells. Journal of Ovarian Research 2014; 7(1) doi: 10.1186/s13048-014-0078-2
|
| 7 |
Manoj Singh, Vikas Kumar, Nirmala Sehrawat, Mukesh Yadav, Mayank Chaudhary, Sushil K. Upadhyay, Sunil Kumar, Varruchi Sharma, Sandeep Kumar, Neeraj Dilbaghi, Anil K. Sharma. Current paradigms in epigenetic anticancer therapeutics and future challenges. Seminars in Cancer Biology 2022; 83: 422 doi: 10.1016/j.semcancer.2021.03.013
|
| 8 |
Millena Prata Jammal, Agrimaldo Martins-Filho, Thales Parenti Silveira, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Cytokines and Prognostic Factors in Epithelial Ovarian Cancer. Clinical Medicine Insights: Oncology 2016; 10 doi: 10.4137/CMO.S38333
|
| 9 |
Chanitra Thuwajit, Alessandra Ferraresi, Rossella Titone, Peti Thuwajit, Ciro Isidoro. The metabolic cross‐talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: Autophagy plays a role. Medicinal Research Reviews 2018; 38(4): 1235 doi: 10.1002/med.21473
|
| 10 |
Nkechiyere G. Nwani, Livia E. Sima, Wilberto Nieves-Neira, Daniela Matei. Targeting the Microenvironment in High Grade Serous Ovarian Cancer. Cancers 2018; 10(8): 266 doi: 10.3390/cancers10080266
|
| 11 |
Rebeca Gonzalez-Pastor, Peter S. Goedegebuure, David T. Curiel. Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer. Cancer Gene Therapy 2021; 28(5): 375 doi: 10.1038/s41417-020-00227-y
|
| 12 |
Boris Winterhoff, Luisa Freyer, Edward Hammond, Shailendra Giri, Susmita Mondal, Debarshi Roy, Attila Teoman, Sally A. Mullany, Robert Hoffmann, Antonia von Bismarck, Jeremy Chien, Matthew S. Block, Michael Millward, Darryn Bampton, Keith Dredge, Viji Shridhar. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. European Journal of Cancer 2015; 51(7): 879 doi: 10.1016/j.ejca.2015.02.007
|
| 13 |
Ercan Cacan. Epigenetic‐mediated immune suppression of positive co‐stimulatory molecules in chemoresistant ovarian cancer cells. Cell Biology International 2017; 41(3): 328 doi: 10.1002/cbin.10729
|
| 14 |
Qilian Yang, Yuqing Yang, Nianxin Zhou, Kexin Tang, Wayne Bond Lau, Bonnie Lau, Wei Wang, Lian Xu, Zhengnan Yang, Shuang Huang, Xin Wang, Tao Yi, Xia Zhao, Yuquan Wei, Hongjing Wang, Linjie Zhao, Shengtao Zhou. Epigenetics in ovarian cancer: premise, properties, and perspectives. Molecular Cancer 2018; 17(1) doi: 10.1186/s12943-018-0855-4
|
| 15 |
Hiroki Fujimoto, Masato Yoshihara, Raymond Rodgers, Shohei Iyoshi, Kazumasa Mogi, Emiri Miyamoto, Sae Hayakawa, Maia Hayashi, Satoshi Nomura, Kazuhisa Kitami, Kaname Uno, Mai Sugiyama, Yoshihiro Koya, Yoshihiko Yamakita, Akihiro Nawa, Atsushi Enomoto, Carmela Ricciardelli, Hiroaki Kajiyama. Tumor-associated fibrosis: a unique mechanism promoting ovarian cancer metastasis and peritoneal dissemination. Cancer and Metastasis Reviews 2024; 43(3): 1037 doi: 10.1007/s10555-024-10169-8
|